ECDC-EMA statement on updating COVID-19 vaccines composition for new SARS-CoV-2 virus variants - ISS-G20 Laboratorium Repository

ECDC and EMA have issued a joint statement on adapted COVID-19 vaccines and considerations for their use during the upcoming autumn 2023 vaccination campaigns.

Currently authorised vaccines continue to be effective at preventing hospitalisation, severe disease and death due to COVID-19. However, protection against the virus declines over time as new SARS-CoV-2 variants emerge.

Entire content available on: https://www.ecdc.europa.eu/en/news-events/ecdc-ema-statement-updating-covid-19-vaccines-composition-new-sars-cov-2-virus-variants